The content on this page was provided by an independent third party and syndicated by XPR Media. Members of the editorial and news staff of the USA TODAY Network were not involved in the creation of this content.

Medicus Pharma Ltd. To Present at Brookline Capital Markets

The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix, a next generation GnRH Antagonist as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer

D-MNA and Teverelix collectively represent ~$8 billion in potential market opportunity

PHILADELPHIA, PA / ACCESS Newswire / September 24, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that members of its executive management team will participate in a live fireside chat on Monday, September 29, 2025, hosted by Kumaraguru (Kumar) Raja, Ph.D., Senior Biotechnology Analyst at Brookline Capital Markets.

Event:

Fireside Chat with Kumar Raja, Ph.D, Brookline Capital Markets Senior Biotech Analyst

Date:

Monday, September 29, 2025

Time:

11:00 a.m. to 12:00 p.m. Eastern Time

Registration:

https://us02web.zoom.us/meeting/register/mhqmY5t1TrqAoxSRCyVXFg

Following a company overview from Dr. Raza Bokhari Executive Chairman and CEO of Medicus Pharma, there will be two featured presentations providing updates on the Company’s key development programs:

  • Ed Brennan, MD, FACS Chief Scientific Officer & Head of R&D Program, will discuss SkinJect™ D-MNA novel treatment to non-invasively treat basal cell carcinoma (BCC) of the skin and provide an update on the progress of phase 2 clinical studies.

  • Faisal Mehmud, MD, MRCP, Chief Medical Officer, will provide an update on Teverelix, a next generation GnRH antagonist as a first in class market product to prevent relapse of acute urinary retention (AURr) and high CV risk prostate cancer.

The fireside chat will conclude with a Q&A session during which participants can ask questions live or submit them during the webcast. Please note this event will be live only; there will be no publicly available recording or archived webcast.

The Company’s lead asset, SkinJect Inc., is a development stage biotechnology company focused on commercializing a novel treatment for non-melanoma skin cancer, especially BCC, using a patented dissolvable doxorubicin-containing microneedle array (D-MNA). D-MNA delivers the chemotherapeutic agent transdermally at the site of the lesion to eradicate tumor cells.

The Company is currently conducting a Phase 2 clinical study for SKNJCT-003 in nine (9) clinical sites across the United States which commenced randomizing patients in August 2024. In March 2025, the Company also announced a positively trending interim analysis for SKNJCT-003 demonstrating more than 60% clinical clearance. The interim analysis was conducted after more than 50% of the then-targeted 60 patients in the study were randomized. The findings of the interim analysis are preliminary and may or may not correlate with the findings of the study once completed. In April 2025, the investigational review board increased the number of participants in SKNJCT-003 to ninety (90) subjects. The Company is expanding its trial sites in Europe and has randomized more than 75% of the ninety (90) participants expected to be randomized in the study.

The Company also has a clinical study (SKNJCT-004) currently underway in the United Arab Emirates (UAE). The study is expected to randomize thirty-six (36) patients in six (6) sites in the UAE. Cleveland Clinic Abu Dhabi (CCAD) is the principal investigator, along with Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), Rashid Hospital (RH), Clemenceau Medical Center (CMC) and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

For further information contact:
Carolyn Bonner, President
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicspharma.com

About Medicus Pharma Ltd.
Medicus Pharma Ltd. (NASDAQ:MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries, spread over three continents.

SkinJect Inc. a wholly owned subsidiary of Medicus Pharma Ltd., is a development stage, life sciences company focused on commercializing novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumors cells. The Company completed a phase 1 safety & tolerability study (SKNJCT-001) in March of 2021, which met its primary objective of safety and tolerability; the study also describes the efficacy of the investigational product D-MNA, with six (6) participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

In August 2025, the Company announced its entry into a non-binding memorandum of understanding (the “MoU”) with Helix Nanotechnologies, Inc. (“HelixNano”), a Boston Based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as a first in market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Antev’s flagship drug candidate is Teverelix trifluoroacetate (Teverelix TFA), a long-acting gonadotrophin-releasing hormone (GnRH) antagonist. Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in fifty (50) patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met with the probability dropping to 82.5% by Day 42.

In January 2023, the FDA, reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

In December 2023, FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

In November 2024, FDA approved the Phase 2b study design in acute urinary retention covering 390 patients.

Cautionary Notice on Forward-Looking Statements
Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr and high CV risk prostate cancer, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the commencement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. . Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

SOURCE: Medicus Pharma Ltd

View the original press release on ACCESS Newswire

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@xpr.media

Georgia’s Lanier Islands Resort Announces Return of Magical Nights of Lights

Georgia’s Lanier Islands Resort Announces Return of Magical Nights of Lights

Oct. 8, 2025 / PRZen / BUFORD, Ga. — For nearly 30 years, Georgians and Peach State visitors enjoyed a beloved holiday tradition – the…

October 10, 2025

Wisconsin Homeowners Urged to Prepare Foundations for Winter as Freeze-Thaw Cycles Threaten Structural Integrity

Wisconsin Homeowners Urged to Prepare Foundations for Winter as Freeze-Thaw Cycles Threaten Structural Integrity

NEENAH, WI – October 08, 2025 – PRESSADVANTAGE – With Wisconsin’s harsh winter season approaching, foundation repair experts at ABT Foundation Solutions, Inc. are advising…

October 10, 2025

WhiteSands Treatment Center Publishes New Resource Addressing Health Insurance Coverage for Alcohol Rehab Treatment

WhiteSands Treatment Center Publishes New Resource Addressing Health Insurance Coverage for Alcohol Rehab Treatment

PALM HARBOR, FL – October 08, 2025 – PRESSADVANTAGE – WhiteSands Alcohol & Drug Rehab has released a new educational resource, titled “Does Health Insurance…

October 10, 2025

M42 Announces an Agreement to Acquire Stake in Drone Defense Company Epirus

M42 Announces an Agreement to Acquire Stake in Drone Defense Company Epirus

DALLAS, TX / ACCESS Newswire / October 9, 2025 / Messier 42 LLC (“M42”), a private leading global artificial intelligence technology and digital transformation company,…

October 10, 2025

Paschal Air, Plumbing & Electric Named Official Air, Plumbing & Electric Provider of the Arkansas Razorbacks

Paschal Air, Plumbing & Electric Named Official Air, Plumbing & Electric Provider of the Arkansas Razorbacks

Springdale, AR October 09, 2025 –(PR.com)– Paschal Air, Plumbing & Electric is proud to announce its partnership as the official Air, Plumbing & Electric provider…

October 10, 2025

House Cleaning Raleigh Pros Highlights Procedural Advancements in Deep Cleaning Programs

House Cleaning Raleigh Pros Highlights Procedural Advancements in Deep Cleaning Programs

Raleigh, North Carolina – October 09, 2025 – PRESSADVANTAGE – House Cleaning Raleigh Pros, a residential cleaning provider based in Raleigh, has announced an operational…

October 10, 2025

Resurgence Publishes New Resource Explaining How Medication-Assisted Treatment Supports Recovery

Resurgence Publishes New Resource Explaining How Medication-Assisted Treatment Supports Recovery

JURUPA VALLEY, CA – October 09, 2025 – PRESSADVANTAGE – Riverside, CA – Resurgence Alcohol & Drug Rehab Riverside has released a new educational resource…

October 10, 2025

Dolan Roofing & Construction Appoints Operations Manager to Central Texas Roofing Contractors Association Board

Dolan Roofing & Construction Appoints Operations Manager to Central Texas Roofing Contractors Association Board

October 09, 2025 – PRESSADVANTAGE – Dolan Roofing & Construction, a family-owned roofing company serving San Antonio since 2016, announces the appointment of Operations Manager…

October 10, 2025

Children First Family Law Introduces Comprehensive Divorce Mediation Model to Help  Families Resolve Conflict Peacefully

Children First Family Law Introduces Comprehensive Divorce Mediation Model to Help Families Resolve Conflict Peacefully

ARVADA, CO – October 09, 2025 – PRESSADVANTAGE – In her latest article, “The Benefits of Full-Service Divorce Mediation in Colorado: How to Save Money,…

October 10, 2025

Austin, TX Homeowners See New Solution to Rising Energy Bills

Austin, TX Homeowners See New Solution to Rising Energy Bills

GIDDINGS, TX – October 09, 2025 – PRESSADVANTAGE – As fall temperatures approach and colder weather looms, property owners across Central Texas are preparing for…

October 10, 2025

Addison Care Debuts at athenahealth 2025 Thrive Conference: 3D Virtual Caregiver Tackles Global Healthcare Crisis of Non-Adherence and Workforce Shortages

Addison Care Debuts at athenahealth 2025 Thrive Conference: 3D Virtual Caregiver Tackles Global Healthcare Crisis of Non-Adherence and Workforce Shortages

LAS CRUCES, NEW MEXICO / ACCESS Newswire / October 9, 2025 / The healthcare industry is approaching a breaking point. Across the globe, 2.7 billion…

October 10, 2025

Smart Medigap Plans Expands Medicare Supplement Offerings for Texans Turning 65

Smart Medigap Plans Expands Medicare Supplement Offerings for Texans Turning 65

Haslet, TX – October 09, 2025 – PRESSADVANTAGE – Smart Medigap Plans, an independent Medicare insurance agency based in Texas, has expanded its portfolio of…

October 10, 2025

USA Cabinet Store Announces Expanded Virtual Design Services for 2025 Fall Remodeling Season

USA Cabinet Store Announces Expanded Virtual Design Services for 2025 Fall Remodeling Season

FAIRFAX, VA – October 09, 2025 – PRESSADVANTAGE – USA Cabinet Store, a kitchen and bath remodeling service provider serving the greater Washington DC metropolitan…

October 10, 2025

Arrowhead Clinic Chiropractor Marietta Expands Same-Day Appointment Availability for Accident Victims

Arrowhead Clinic Chiropractor Marietta Expands Same-Day Appointment Availability for Accident Victims

Marietta, Georgia – October 09, 2025 – PRESSADVANTAGE – Arrowhead Clinic Chiropractor Marietta has expanded its same-day appointment availability to better serve accident victims requiring…

October 10, 2025

The Wedding Planner Hong Kong Announces Expansion of Party Planning Services under Its Event Planner Portfolio

The Wedding Planner Hong Kong Announces Expansion of Party Planning Services under Its Event Planner Portfolio

HONG KONG, HK – October 09, 2025 – PRESSADVANTAGE – The Wedding Planner Hong Kong has formally expanded its service offerings to include a party…

October 10, 2025

New Resource on Dangers of Fentanyl and Meth Published by Muse Treatment

New Resource on Dangers of Fentanyl and Meth Published by Muse Treatment

LOS ANGELES, CA – October 09, 2025 – PRESSADVANTAGE – Muse Treatment Alcohol & Drug Rehab has released a new resource on its website titled…

October 10, 2025

Fixed Braces Dentist Announces Consultations for Teeth Straightening at Taylored Dental Care

Fixed Braces Dentist Announces Consultations for Teeth Straightening at Taylored Dental Care

Bradford, England – October 09, 2025 – PRESSADVANTAGE – Taylored Dental Care has announced that it is now offering dedicated consultations for patients considering fixed…

October 10, 2025

Spray Foam Insulation Service Broadens Reach for Energy Savings

Spray Foam Insulation Service Broadens Reach for Energy Savings

ALPINE, WY – October 09, 2025 – PRESSADVANTAGE – High Country Solutions, owned by Skeeter Aimone, has announced the expansion of its spray foam insulation…

October 10, 2025

Evergreen Construction Expands Comprehensive Handyman Renovation Services

Evergreen Construction Expands Comprehensive Handyman Renovation Services

October 09, 2025 – PRESSADVANTAGE – Evergreen Construction, a licensed and insured home remodeling company serving Southwest Missouri since 2022, announces the expansion of its…

October 10, 2025

Big Easy Paintings Announces Free Estimates for Painting Projects

Big Easy Paintings Announces Free Estimates for Painting Projects

NEW ORLEANS, LA – October 09, 2025 – PRESSADVANTAGE – Big Easy Paintings announced the elimination of estimate fees for painting projects across its ten-community…

October 10, 2025

Silverback AI Chatbot Announces New AI Agents Feature for Conversational Automation

Silverback AI Chatbot Announces New AI Agents Feature for Conversational Automation

New York, New York – October 09, 2025 – PRESSADVANTAGE – Silverback AI Chatbot today announced the release of its AI Agents feature, designed to…

October 10, 2025

FDA-Compliant Molecular Marking Positions SMX to Dominate the $824B Global Recycling Market (NASDAQ: SMX)

FDA-Compliant Molecular Marking Positions SMX to Dominate the $824B Global Recycling Market (NASDAQ: SMX)

NEW YORK, NY / ACCESS Newswire / October 9, 2025 / The plastics market is enormous – an $824 billion global economy in constant motion,…

October 10, 2025

PRO EM National Event Services Announces Acquisition of Top Productions, Expanding Flooring and Scaffolding Capabilities on the West Coast

PRO EM National Event Services Announces Acquisition of Top Productions, Expanding Flooring and Scaffolding Capabilities on the West Coast

Phoenix, AZ October 09, 2025 –(PR.com)– PRO EM National Event Services, a national leader in premium event rental solutions, proudly announces the acquisition of Top…

October 10, 2025

TripGift(R) Unlocks Global Bucket List’ Dreams With Launch of New Destination Gift Card SKUs and Marketplaces for Cities, Destinations and Experiences

TripGift(R) Unlocks Global Bucket List’ Dreams With Launch of New Destination Gift Card SKUs and Marketplaces for Cities, Destinations and Experiences

Travel Commerce Innovation Winner delivers New York, Los Angeles, Miami, London, Paris, Dubai, Tokyo Destination Marketplaces and Bucket List Experience Packages in 103 currencies. NEW…

October 10, 2025

Atlas Salt Issues Compensation Securities

Atlas Salt Issues Compensation Securities

ST. GEORGE’S, NEWFOUNDLAND AND LABRADOR / ACCESS Newswire / September 19, 2025 / Atlas Salt Inc. (“Atlas Salt” or the “Company”) (TSXV:SALT)(OTCQB:REMRF) announces the issuance…

October 10, 2025

Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories

Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories

CAMBRIDGE, MA / ACCESS Newswire / September 19, 2025 / Moderna announced today that the first mRNA vaccines fully manufactured in Canada are being shipped…

October 10, 2025

A Taste of Italy Like Never Before Hits Long Island

A Taste of Italy Like Never Before Hits Long Island

Farmingville, NY October 08, 2025 –(PR.com)– Long Island is about to experience a whole new kind of Italian celebration! The inaugural San Gennaro Wine &…

October 10, 2025

True North Social Enhances SEO Agency Capabilities for Comprehensive Digital Marketing Solutions

True North Social Enhances SEO Agency Capabilities for Comprehensive Digital Marketing Solutions

CULVER CITY, CA – October 10, 2025 – PRESSADVANTAGE – True North Social, a full-service digital marketing agency, announces the expansion of its search engine…

October 10, 2025

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells

New findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to cell death through iron-dependent regulation. MIAMI,…

October 10, 2025

Revolve Expands Mexico Distributed Generation Business with New Partnership

Revolve Expands Mexico Distributed Generation Business with New Partnership

VANCOUVER, BC / ACCESS Newswire / October 9, 2025 / Revolve Renewable Power Corp. (TSXV:REVV)(OTCQB:REVVF) (“Revolve” or the “Company“), a North American owner, operator and…

October 10, 2025

New Data Shows Drop in Fatal Overdoses; WhiteSands Treatment Providers Respond

New Data Shows Drop in Fatal Overdoses; WhiteSands Treatment Providers Respond

Tampa, Florida – September 17, 2025 – (PRESS ADVANTAGE) – WhiteSands Treatment highlights new data: the Sunshine State had a near 10 percent decline in…

October 10, 2025

LHH’s General Assembly and EZRA Brands Launch AI Leadership Transformation Program: Pioneering Multi-Faceted Learning for Future-Ready Leaders

LHH’s General Assembly and EZRA Brands Launch AI Leadership Transformation Program: Pioneering Multi-Faceted Learning for Future-Ready Leaders

Only 34% of global leaders have undergone AI-specific leadership training. This new program bridges this gap, empowering leaders to confidently steer AI-driven change. NEW YORK…

October 10, 2025

Boston Industrial Solutions’ Natron® XG Series Ink Exceeds Global Safety Compliance

Boston Industrial Solutions’ Natron® XG Series Ink Exceeds Global Safety Compliance

Oct. 8, 2025 / PRZen / WOBURN, Mass. — Boston Industrial Solutions, Inc. is proud to announce that the Natron® XG Series ink has passed…

October 10, 2025

Special Eyes Optical Helps Parents Find the Right Size Glasses for Kids with Expert Guidance

Special Eyes Optical Helps Parents Find the Right Size Glasses for Kids with Expert Guidance

October 07, 2025 – PRESSADVANTAGE – Special Eyes Optical, North Texas’ premier eyewear shop exclusively for children, is offering expert guidance to parents navigating the…

October 10, 2025

Preston Hollow Cleaning Services Expands Office Cleaning Service Portfolio to Meet Growing Business Demand

Preston Hollow Cleaning Services Expands Office Cleaning Service Portfolio to Meet Growing Business Demand

MESQUITE, TX – October 09, 2025 – PRESSADVANTAGE – Preston Hollow Cleaning Services, a leading commercial cleaning provider serving the Dallas-Fort Worth metroplex, today announced…

October 10, 2025

Dr. Steven Tersigni’s WCRS Board Certification Sets a New Standard in LASIK Care

Dr. Steven Tersigni’s WCRS Board Certification Sets a New Standard in LASIK Care

Lake Oswego, OR – October 09, 2025 – PRESSADVANTAGE – Tersigni Vision is drawing attention to a critical credential that sets its founder, Dr. Steven…

October 10, 2025

MidSolid Challenges Beauty Industry Norms with Launch of High-Performance, pH-Balanced Solid Conditioner Line

MidSolid Challenges Beauty Industry Norms with Launch of High-Performance, pH-Balanced Solid Conditioner Line

HIGHLANDS RANCH, CO – October 08, 2025 – PRESSADVANTAGE – MidSolid, an innovator in sustainable personal care, today announced the launch of its new Solid…

October 10, 2025

Manor Works Painting Recognized for Outstanding Customer Reviews

Manor Works Painting Recognized for Outstanding Customer Reviews

October 07, 2025 – PRESSADVANTAGE – Manor Works Painting, a family-owned residential painting company serving Northern Virginia since 1998, today announced that it had received…

October 10, 2025

Brickell Rheumatology Wellness Center Enhances Integrative Treatment Approach for Rheumatology Patients

Brickell Rheumatology Wellness Center Enhances Integrative Treatment Approach for Rheumatology Patients

MIAMI, FL – October 07, 2025 – PRESSADVANTAGE – Brickell Rheumatology Wellness Center enhances patient-centered care through an integrative, functional medicine-informed approach to rheumatology, offering…

October 10, 2025

Amana Care Clinic – Muscatine Expands Urgent Care Services with Enhanced Telehealth Platform

Amana Care Clinic – Muscatine Expands Urgent Care Services with Enhanced Telehealth Platform

MUSCATINE, IA – October 07, 2025 – PRESSADVANTAGE – Amana Care Clinic – Muscatine, an urgent care clinic, has introduced enhanced telehealth services to complement…

October 10, 2025